3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
34
Lymphoma, Non-Hodgkin
25
Lymphoma, Follicular
25
Lymphoma, Large B-Cell, Diffuse
23
Lymphoma, Mantle-Cell
16
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Lymphoma, Large-Cell, Immunoblastic
8
Waldenstrom Macroglobulinemia
6
Lymphoma, B-Cell
5
Burkitt Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
2
Lymphoma, Large-Cell, Anaplastic
2
Leukemia
2
Orbital lymphoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Graft vs Host Disease
1
Interventions
Cyclophosphamide
4
Gemcitabine
3
isatuximab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Rituximab
2
Lenalidomide
2
Dexamethasone
2
Cisplatin
2
trametinib
1
spartalizumab
1
pomalidomide
1
pertuzumab
1
penpulimab
1
pembrolizumab
1
olaparib
1
niraparib
1
lutetium Lu 177 dotatate
1
ibritumomab tiuxetan
1
fludarabine
1
dabrafenib
1
copper dotatate CU-64
1
Trastuzumab
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Histologic Type
×
ibritumomab tiuxetan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts